InvestSMART

Artrya Limited (ASX:AYA)

ALERT: Price-sensitive ASX Announcement for AYA
Current share price for AYA : $5.640 1.81 (47.26%)+
Announcement
Release
27 Oct 2025 9:29AM
Price at Release
$3.830
Full Release
download
Summary
Artrya Limited, an Australian medical technology company, is actively advancing its Salix® AI-powered platform for coronary artery disease management with significant strides made during the quarter ending September 30, 2025. Key developments include securing FDA clearance for its Coronary Plaque module, establishing a commercial relationship with Tanner Health, and raising A$80 million to support US market entry. With a quarter-end cash position of A$62.8 million, Artrya is poised to expand its US market presence and has set a strategic course for future growth, including the SAPPHIRE study aimed at enhancing coronary disease diagnostics.
Key Points
  • Artrya Limited is advancing its commercial and regulatory activities, focusing on its Salix® AI-powered platform for coronary artery disease management.
  • During the quarter ending 30 September 2025, Artrya secured FDA clearance for its Salix® Coronary Plaque module, allowing for US category 1 CPT reimbursement.
  • The company completed its first integration with a US health system, Tanner Health, under a five-year agreement.
  • Artrya raised A$80 million to support its US commercial launch and strengthen its balance sheet.
  • The company reported cash at the end of the quarter amounting to A$62.8 million.
  • Artrya is focused on establishing commercial agreements with US healthcare systems and expanding its US market presence.
  • The SAPPHIRE study, which is aimed at improving coronary artery disease detection, is set to commence in 2026 with confirmed partners Piedmont Healthcare and Huntsville Hospital Heart Centre.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.